Vertex Pharmaceuticals Inc (VRTX)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	17,580,400	16,512,800	15,470,200	14,432,300	13,912,700	13,029,600	11,933,500	10,907,000	10,100,000	9,530,800	9,196,400	8,980,300	8,686,800	8,133,470	7,519,240	6,461,650	6,085,200	5,253,390	5,069,960	4,723,310
Debt-to-equity ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $17,580,400K
= 0.00

The debt-to-equity ratio of Vertex Pharmaceuticals, Inc. has been relatively consistent and low over the past eight quarters, indicating a conservative approach in financing its operations. The company maintains a healthy balance between debt and equity, with the ratio fluctuating between 0.02 and 0.05. This suggests that Vertex relies more on equity financing rather than debt to fund its activities. Overall, the stability and low levels of the debt-to-equity ratio indicate a strong financial position and ability to manage its debt obligations effectively.